The estimated Net Worth of Todd P. Branning is at least $11.3 Mille dollars as of 18 March 2022. Todd Branning owns over 10,000 units of NeuBase Therapeutics stock worth over $11,340 and over the last 6 years Todd sold NBSE stock worth over $0.
Sign up
Todd Branning NBSE stock SEC Form 4 insiders trading
Todd has made over 3 trades of the NeuBase Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Todd bought 10,000 units of NBSE stock worth $18,100 on 18 March 2022.
The largest trade Todd's ever made was exercising 20,096 units of NeuBase Therapeutics stock on 22 January 2020 worth over $7,596. On average, Todd trades about 4,554 units every 71 days since 2019. As of 18 March 2022 Todd still owns at least 30,000 units of NeuBase Therapeutics stock.
You can see the complete history of Todd Branning stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Todd Branning's mailing address?
Todd's mailing address filed with the SEC is C/O 350 TECHNOLOGY DRIVE, FOURTH FLOOR, , PITTSBURGH, PA, 15219.
Insiders trading at NeuBase Therapeutics
Over the last 5 years, insiders at NeuBase Therapeutics have traded over $713,184 worth of NeuBase Therapeutics stock and bought 177,514 units worth $548,788 . The most active insiders traders include Dov A Md Goldstein, Dietrich A Stephan e Samuel Backenroth. On average, NeuBase Therapeutics executives and independent directors trade stock every 56 days with the average trade being worth of $37,929. The most recent stock trade was executed by Corp Symetryx on 14 September 2023, trading 282,445 units of NBSE stock currently worth $375,652.
What does NeuBase Therapeutics do?
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
What does NeuBase Therapeutics's logo look like?
Complete history of Todd Branning stock trades at Amneal Pharmaceuticals Inc, Phathom Pharmaceuticals Inc e NeuBase Therapeutics
NeuBase Therapeutics executives and stock owners
NeuBase Therapeutics executives and other stock owners filed with the SEC include:
-
Dietrich Stephan,
President, Chief Executive Officer, Director -
Sam Backenroth,
Chief Financial Officer, Treasurer, Secretary -
Eric Richman,
Independent Director -
Franklyn Prendergast,
Independent Director -
Diego Miralles,
Independent Director -
Dov Goldstein,
Independent Director -
Dr. Dietrich A. Stephan Ph.D.,
Founder, Pres, CEO, Chairman & Interim CFO -
Dr. William Roland Mann MBA, Ph.D.,
Chief Operating Officer -
Samuel Backenroth,
CFO, Treasurer & Sec. -
Dan Ferry,
IR Contact Officer -
William Mann,
Chief Operating Officer -
Dr. Sandra Rojas-Caro M.D.,
Chief Medical Officer -
Shannon McCarthy,
Chief People Officer -
Alan Scrivner J.D.,
VP of IP & Legal -
Dr. Anthony Rossomando Ph.D.,
Chief Technology Officer -
Dr. Robert Zamboni Ph.D.,
Chief of Preclinical Devel. & Member of Scientific Advisory Board -
Dr. Robert Friedlander M.D.,
Consulting Chief Medical Officer -
Dr. Curt Bradshaw Ph.D.,
Chief Scientific Officer -
Eric J Ende,
Director -
Curt Bradshaw,
Chief Scientific Officer -
Gerald J Mc Dougall,
Director -
Kianoush Motesharei,
See Remarks -
Todd P. Branning,
Chief Financial Officer -
Corp Symetryx,
10% owner -
Dietrich A Stephan,
Founder and CEO